Healthcare

Dimerix Limited (ASX:DXB)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.2750 (0%)

(as on 2021-10-23 05:15:27)

Market Cap : AUD 88.24 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.275 0.28 0.275 0.275L 0.28 H 0.175L 0.48 H
Last Trade 0.275
Change% 0.0000
52 W H/L 0.48/0.175
EBITDA -10.884 M
NPAT After Abnormal Items -6.372 M
Equity 1.468 M
ROE% -433.89%
Total Liabilities 7.952 M
Total Revenue 4.555 M
Cash and Cash Equivalents 5.25 M

Stock Information

Share price 0.275
Market Cap 88.24 M
Price/Gross Cash Flow -8.74
Dividend Yield Excluding Special 0.00%
Ending Shares 197.999 M
52-Week Range 0.175-0.48
P/E ratio 0.000
Sector P/E --
EPS -3.22
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.02
Net Gearing -10.69%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.00
Book Value Per Share 0.01

Announcements

Heading Date/Time
First Approvals Received for Start of Phase 3 FSGS Trial  21/10/2021 8:38AM
Phase 3 DMX-200 COVID-19 Study Expands into Australia  15/10/2021 10:00AM
Change in substantial holding  07/10/2021 8:23AM
Becoming a substantial holder  05/10/2021 4:00PM
Secondary Trading Notice Pursuant to Section 708A(5)(e)  05/10/2021 11:49AM
Change of Director's Interest Notices - JW, HA, SP and NW  05/10/2021 11:41AM
Notification regarding unquoted securities - DXB  05/10/2021 11:19AM
Notification regarding unquoted securities - DXB  05/10/2021 11:15AM
Notification regarding unquoted securities - DXB  05/10/2021 11:10AM
Notification regarding unquoted securities - DXB  05/10/2021 11:04AM
Application for quotation of securities - DXB  05/10/2021 11:00AM
Application for quotation of securities - DXB  05/10/2021 10:57AM
Dimerix Closes SPP Oversubscribed  01/10/2021 9:17AM
Results of Meeting  27/09/2021 3:14PM
AGM Presentation  27/09/2021 2:06PM
CEO's Address to Shareholders  27/09/2021 2:06PM
Virtual Meeting Voting and Registration Guide  27/09/2021 8:49AM
DMX-200 CLARITY COVID-19 Study Approval in India  24/09/2021 9:55AM
Change of Director's Interest Notices - JW, HA and SP  15/09/2021 3:16PM
Change in substantial holding  03/09/2021 12:48PM
Phase 3 Study in FSGS Kidney Patients Commences  25/08/2021 8:42AM
Notice of Annual General Meeting/Proxy Form  24/08/2021 9:20AM
Annual General Meeting - Notice and Letter to Shareholders  24/08/2021 9:13AM
SPP and Options Prospectus  24/08/2021 9:06AM
Secondary Trading Notice Pursuant to Section 708A(5)(e)  24/08/2021 8:26AM
Application for quotation of securities - DXB  24/08/2021 8:22AM
Application for quotation of securities - DXB  24/08/2021 8:18AM
Response to ASX Query  19/08/2021 11:26AM
Secondary Trading Notice Pursuant to Section 708A(5)(e)  18/08/2021 2:14PM

Similar Companies

Related Articles

Load More

About Company

Dimerix Limited (ASX: DXB), is a clinical stage, biotechnology company that focusses on the development of new therapeutic treatments using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology (HIT).

Corporate Information

company address 425 Smith Street, FITZROY, VIC, AUSTRALIA, 3065

company phone+61 8 9388 8290

company websitehttp://www.dimerix.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-15 2022
Report (Prelim) 2022-08-15 2022
Report (Interim) 2022-02-21 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 4.555 M 2.422 M 1.429 M 825,104 536,335
Total Revenue 4.555 M 2.422 M 1.429 M 825,104 536,335
Interest Income 1,506 2,700 18,108 20,184 18,282
Interest Expenses 0 0 0 0 0
Expenses -10.884 M -6.905 M -4.329 M -4.159 M -2.312 M
EBITDA -6.329 M -4.483 M -2.9 M -3.333 M -1.775 M
Depreciation and Amortization -44,601 -13,529 -4,677 -6,422 -1,520
Depreciation -44,601 -13,529 -4,677 -6,422 -1,520
Amortisation 0 0 0 0 0
EBIT -6.373 M -4.497 M -2.904 M -3.34 M -1.777 M
Pre Tax Profit -6.372 M -4.494 M -2.886 M -3.32 M -1.759 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -6.372 M -4.494 M -2.886 M -3.32 M -1.759 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items -6.372 M -4.494 M -2.886 M -3.32 M -1.759 M
Ending Shares 197.999 M 197.749 M 158.799 M 155.049 M 96.07 M
Weighted Average Shares 197.877 M 171.519 M 158.614 M 115.416 M 85.24 M
EPS After Abnormal Items (cents) -3.22 -2.62 -1.82 -2.88 -2.06
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 9.419 M 10.388 M 4.938 M 7.264 M 2.869 M
Total Non Current Assets 1,422 1,232 2,620 391 3,270
Total Assets 9.421 M 10.389 M 4.941 M 7.265 M 2.872 M
Total Current Liabilities 7.952 M 2.63 M 737,768 406,744 242,118
Total Non Current Liabilities 0 0 0 0 0
Total Liabilities 7.952 M 2.63 M 737,768 406,744 242,118
Net Assets 1.468 M 7.759 M 4.203 M 6.858 M 2.63 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -6.36 M -4.721 M -2.751 M -3.225 M -1.864 M
Net Invested Cash 4,379 0 -6,906 -3,543 -2,581
Net Financing Cash Flows 3.825 M 8.911 M 0 7.247 M 2.093 M
Beginning Cash 7.786 M 3.563 M 6.284 M 2.245 M 2.019 M
End Cash Position 5.25 M 7.786 M 3.563 M 6.284 M 2.245 M
Exchange Rate Adjustments -4,862 32,808 36,672 21,645 0
Other Cash Adjustments 0 0 0 0 0
Ending Cash 5.25 M 7.786 M 3.563 M 6.284 M 2.245 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK